Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() Companion Diagnostic Market is poised to grow at a rate of ~13% by 2027The Companion Diagnostic Market is projected to grow at ~13% by 2027, fueled by personalized medicine, medical tech advancements, affordable genetic tests, increasing adverse drug reactions, and demand for next-gen sequencing.
Growing Demand for NGS-Based Technology Drives the Companion Diagnostics Market The growing demand for next-generation sequencing technology specifically its capability to identify rare variants is crucial to continuing success and the wider distribution of companion diagnostics solutions in the market. The use of NGS panels in one test has the potential to help in the treatment of several different types of cancers. For instance, § In July 2022, Almac Diagnostic partnered with AstraZeneca to develop and commercialize multiple companion diagnostic (CDx) products based on NGS and qPCR-based technologies Companion Diagnostics for Targeted Cancer Drugs Drives Companion Diagnostics Market Demand According to clinical research, 75% of cancer patients do not respond well to the same cancer treatment. In such cases, companion diagnostic tests help to indicate the presence of a molecular target and can also reveal the off-target effects of a therapeutic, predicting toxicities and adverse effects associated with a drug. Potential Role of Companion Diagnostics in Precision Medicine Drives the Companion Diagnostics Market Personalized medicine the practice of giving the correct dosage of the correct medicines at the correct time. Companion diagnostics, which are used to identify eligible patients for a particular therapy, are a significant driver to enable personalized treatment choices and precision medicine. Companion diagnostics offers numerous advantages in advancement of personalized medicine and improvement of preclinical and clinically focused drug development. North America is expected to hold a large share of the Companion Diagnostics Market North America holds a dominant market share of the companion diagnostics market. This can be primarily attributed to the rising prevalence of diseases like cancer & HIV, improvements in regulatory guidelines, and potential economic benefits for drug developers early in drug development in the region. Competitive Landscape: Companion Diagnostics Market Some of the Key players operating in the market's include Thermo Fischer Scientific Inc., Illumina Inc., Bayer AG, Danaher Corporation, Invitae, and Agilent Technologies, Inc, among others. Get Detailed Insights on Companion Diagnostics Market @ https://meditechinsights.com/ About Medi-Tech Insights Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services. End
|
|